BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
VR23, soluble in warmed DMSO and warmed water and insoluble in ethanol, interferes with the proteasome’s ability to degrade proteins, thereby disrupting cellular processes in cancer cells, particularly multiple myeloma. It targets Caspase-like proteasomes, Chymotrypsin-like proteasomes, and trypsin-like proteasomes.
VR23 is used in research to investigate and inhibit proteasome activity, which is key in regulating protein degradation and cellular processes.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.